NCT04648969View on ClinicalTrials.gov

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 3, 2019

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Hypogonadotropic Hypogonadism
Interventions
DRUG

kisspeptin 112-121

20 intravenous doses of kisspeptin 112-121 (4 different doses of kisspeptin (randomized) in 5 sets)

DRUG

GnRH

1 intravenous dose of GnRH

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Stephanie B. Seminara, MD

OTHER

NCT04648969 - Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism | Biotech Hunter | Biotech Hunter